Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer.
作者： Jong Woo Lee , Young Hwa Soung , Su Young Kim , Won Sang Park , Suk Woo Nam
DOI: 10.1002/IJC.20591
关键词: Somatic cell 、 Egfr mutation 、 Protein kinase domain 、 Exon 、 Molecular biology 、 Lung cancer 、 Lung 、 Amino acid 、 Non small cell 、 Cancer research 、 Biology
摘要: somatic mutations in the adenocarcinomas, bronchioloalveolarcarcinomas and large cell carcinomas of lung that all correlatedwith a clinical response to gefitinib. The were de-tected exon 18, 19 20 encode intracellularkinase domain. detected 18 wouldsubstitute amino acid G719 P-loop, while thosedetected 21 would substitute acids theactivation in-framedeletions may alter structure C helix. All
sci-hub.se 参考文章(7)
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)
K J Williams, B A Telfer, I J Stratford, S R Wedge, ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. British Journal of Cancer. ,vol. 86, pp. 1157- 1161 ,(2002) , 10.1038/SJ.BJC.6600182
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
Robert N Jorissen, Francesca Walker, Normand Pouliot, Thomas PJ Garrett, Colin W Ward, Antony W Burgess, Epidermal growth factor receptor: mechanisms of activation and signalling. Experimental Cell Research. ,vol. 284, pp. 31- 53 ,(2003) , 10.1016/S0014-4827(02)00098-8
Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Jean-Yves Douillard, Yutaka Nishiwaki, Johan Vansteenkiste, Shinzoh Kudoh, Danny Rischin, Richard Eek, Takeshi Horai, Kazumasa Noda, Ichiro Takata, Egbert Smit, Steven Averbuch, Angela Macleod, Andrea Feyereislova, Rui-Ping Dong, José Baselga, None, Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 21, pp. 2237- 2246 ,(2003) , 10.1200/JCO.2003.10.038
J Guillermo Paez, Pasi A Janne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon, Katsuhiko Naoki, Hidefumi Sasaki, Yoshitaka Fujii, Michael J Eck, William R Sellers, Bruce E Johnson, Matthew Meyerson, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. ,vol. 304, pp. 1497- 1500 ,(2004) , 10.1126/SCIENCE.1099314
Fortunato Ciardiello, Sabino De Placido, Grazia Pomatico, A. Raffaele Bianco, Vincenzo Damiano, Rosa Caputo, Roberto Bianco, Giampaolo Tortora, Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor Clinical Cancer Research. ,vol. 6, pp. 2053- 2063 ,(2000)